Trial Profile
Phase III Randomized Multicentre Trial of Carboplatin + Liposomal Doxorubicin vs Carboplatin + Paclitaxel in Patients With Ovarian Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 29 Mar 2023
Price :
$35
*
At a glance
- Drugs Doxorubicin liposomal (Primary) ; Carboplatin; Paclitaxel
- Indications Ovarian cancer
- Focus Therapeutic Use
- Acronyms MITO-2
- 23 Mar 2023 Planned End Date changed from 1 Dec 2017 to 1 Dec 2023.
- 23 Mar 2023 Planned primary completion date changed from 1 Dec 2013 to 1 Dec 2023.
- 14 Jul 2017 Planned End Date changed from 1 May 2016 to 1 Dec 2017.